Navigation Links
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
Date:5/8/2013

igen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the complete study report for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; Orexigen's ability to conduct the Light Study and the progress and timing thereof, including risks associated with enrolling and retaining the appropriate patients in the Light Study; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese patients treated with Contrave does not adversely affect Contrave's benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study; the potential for the FDA to not approve Contrave even after the resubmission with the MACE data; the potential for the Light Study to cost more than what is projected; the potential for early termination of Orexigen's North American collaboration agreement with Takeda Pharmaceutical Company Limited; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; the development plan for Empatic; Orexigen's ability to enter into a collaborative partnership for Empatic on acceptable terms, if at all; and other risks described in Orexigen's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news rele
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
7. Fate Therapeutics Strengthens Its iPSC Platform
8. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
9. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
10. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
11. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... Albany, New York (PRWEB) July 12, 2014 ... market analysis for various reagents used in ... biotechnology is driving the life science reagents ... this study include manufacturers and providers of ... Science Reagents Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . ...
(Date:7/11/2014)... , July 11, 2014 ... to announce the appointment of John P. Donoghue ... Biotech   in  Geneva . The ... Campus Biotech in Geneva , has ... recognised neuroscientists. John P. Donoghue , founder of ...
(Date:7/10/2014)... 2014 Product and process impurities ... abundance and are often “lost in the noise,” ... Join presenters Dr. Rowel Tobias, Senior Scientist, Protein ... Head of Quality at Nanotherapeutics, Inc., to lear ... speed detection and quantitation while achieving the required ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... platform offers multiple diagnostic modalities on a single ... to ... physicians and administrators, SAN DIEGO, March 28 ... of intravascular,ultrasound (IVUS), functional measurement (FM) and Optical Coherence,Tomography (OCT) ...
... /Xinhua-PRNewswire/ -- Tiens Biotech Group (USA),Inc. ("the Company" or ... financial results for the fourth quarter and twelve months ... of 2007 was $13.3 million compared to,$16.6 million for ... the fourth quarter of 2007 was $3.9 million, or ...
... -. Actavis Group, the,international generic pharmaceuticals company, ... approvals from the U.S. Food & Drug ... Distribution,of the products will commence immediately., ... strength, are the generic equivalent of Wellbutrin ...
Cached Biology Technology:Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 2Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 3Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 4Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 5Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 2Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 3Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 4Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 5Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 6Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 7Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 8Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 9Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 10Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S. 2
(Date:7/11/2014)... evidence that under the normal circumstances, astrocytes ... maintain neuronal environment, and exhibit therapeutic and ... disease. Previous studies have found that nerve ... chemical induction have reduced viability, which produces ... Xiaodong Yuan, Kailuan General Hospital, Hebei United ...
(Date:7/11/2014)... , July 11, 2014 Research ... "International Biometrics Technology Market - Industry Analysis Size ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... and crimes has created a need for high level ... used for personnel authentication such as username and passwords, ...
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2Blame it on the astrocytes 2
... has made new links between 29 regions of the genome ... disease (IBD). The new findings increase the total number of ... to 99. The results point to several biological processes, ... the intestinal wall, which are likely to play an important ...
... With millions of people warding off winter,s chill with ... flags about the potential health effects of the smoke ... American Chemical Society,s (ACS,) journal, Chemical Research in ... the lungs from wood smoke may have several adverse ...
... they seem when it comes to fishsomething scientists at the ... Using modern genetic analysis, combined with traditional examination of morphology, ... three species of blenny in the genus Starksia ... in the scientific journal ZooKeys , Feb. 3. ...
Cached Biology News:Research links 29 genome regions with common form of inflammatory bowel disease 2Research links 29 genome regions with common form of inflammatory bowel disease 3Smithsonian scientists discover 7 new species of fish 2